Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-03-01
2005-03-01
Kifle, Bruce (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S114000
Reexamination Certificate
active
06861438
ABSTRACT:
The invention provides a compound of formula I:wherein G, R2, and R3have any of the values defined in the specification, or a pharmaceutically acceptable salt thereof, as well as processes and intermediates useful for preparing such compounds or salts, and methods of treating a herpesvirus infection using such compounds or salts.
REFERENCES:
patent: 4125611 (1978-11-01), Yamade et al.
patent: 4145418 (1979-03-01), Kuwada et al.
patent: 4767766 (1988-08-01), Baker et al.
patent: 4877793 (1989-10-01), Davies
patent: 4959363 (1990-09-01), Wentland
patent: 5155115 (1992-10-01), Suzuki et al.
patent: 5219864 (1993-06-01), Suzuki et al.
patent: 5352685 (1994-10-01), Maruyama et al.
patent: 5593943 (1997-01-01), Nuebling et al.
patent: 5817819 (1998-10-01), Furuya et al.
patent: 6239142 (2001-05-01), Schnute et al.
patent: 6620810 (2003-09-01), Thorarensen
patent: 4227747 (1994-02-01), None
patent: 0046990 (1982-03-01), None
patent: 0269295 (1988-06-01), None
patent: 0443568 (1991-02-01), None
patent: 505058 (1992-09-01), None
patent: 0560348 (1993-09-01), None
patent: 2289276 (1995-11-01), None
patent: 46-032198 (1970-09-01), None
patent: 57116077 (1982-07-01), None
patent: 57142985 (1982-09-01), None
patent: 07076586 (1995-03-01), None
patent: 07076586 (1995-03-01), None
patent: 08301849 (1996-11-01), None
patent: 08301849 (1996-11-01), None
patent: WO-9203427 (1992-03-01), None
patent: WO-9528405 (1995-10-01), None
patent: WO-9618616 (1996-06-01), None
patent: WO-9618617 (1996-06-01), None
patent: WO-9740846 (1997-11-01), None
patent: WO-9811073 (1998-03-01), None
patent: WO-9932450 (1999-07-01), None
patent: WO-9962908 (1999-12-01), None
patent: WO-0007595 (2000-02-01), None
patent: WO-0040561 (2000-07-01), None
patent: WO-0040563 (2000-07-01), None
patent: WO-0053610 (2000-09-01), None
patent: WO-0076990 (2000-12-01), None
patent: WO-0137824 (2001-05-01), None
patent: WO-0158898 (2001-08-01), None
patent: WO-03-020729 (2003-03-01), None
Database Crossfire Beilstein, vol. 26, No. 1, Beilstein Institut zur Foerderung der chemischen Wissenschaften,Frankfurt am Main, DE (1991), 3 pages.
Database Crossfire Beilstein, vol. 21, Beilstein Institut zur Foerderung der chemischen Wissenschaften,Frankfurt am Main, DE (1984) 3 pages.
The Merck Manual of Diagnosis and Therapy, Eleventh Edition, Lyght, C.E., et al., (eds.), Merck & Co.,(1966), pp. 212-213.
Blaskiewicz, P. , et al., “Thienopyridinonecarboxylic Acid Derivatives”,Chemical Abstracts, Abstract of German Patent No. 2,447,477, Abstract No. 85:46627, (1976), 2 pgs.
El-Abadelah, Mustafa M., et al., “Synthesis and Chiroptical Properties of Some N-(2-Chloro-7-cyclopropyl-4,7-dihydro-4-oxo-thieno[2,3-b]pyridine-5-carbonyl) L-a-Amino Ester”,Z. Naturforsch, (1977), pp. 419-426.
Elliott, Richard L., et al., “The Preparation of 2-(Heterocyclyl)thieno[3,2-b]pyridine Derivatives”,Tetrahedron, vol. 43, No. 14, (1987), pp. 3295-3302.
Goerlitzer, K. , et al., “Gyrase inhibitors; Part 3.: Synthesis and reactions of ethyl 1,4-dihydro-4-oxo[1]benzothieno[3,2-b]pyridine-3-carboxylate”,Pharmazie, vol. 55, No. 8, (2000), pp. 595-600.
Nishikawa, Yoshinori , et al., “Synthesis and Antiallergic Activity of N-[4-(4-Diphenylmethyl-1-piperazinyl)butyl]-1,4-dihydro-4-oxopyridine-3-carboxamides”,Chem. Pharm. Bull., vol. 37, No. 5, (1989), pp. 1256-1259.
Patani, G. A., et al., “Bioisosterism: A Rational Approach in Drug Design”,Chemical Reviews, 96(8), (1996), pp. 3147-3176.
Thornber, C. W., “Isosterism and Molecular Modification in Drug Design”,Chemical Socitey Review, vol. 8, No. 4, (1979), pp. 563-580.
Vaillancourt, V A., et al., “Naphthalene carboxamides as inhibitors of human cytomegalovirus DNA polymerase”,Bioorganic&Medicinal Chemistry Letters, vol. 10, No. 18 (2000), pp. 2079-2081.
Larsen Scott D.
May Paul
Romines Karen
Schnute Mark E.
Tanis Steven P.
Kifle Bruce
Pfizer
Schwegman Lundberg Woessner & Kluth P.A.
LandOfFree
Antiviral agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antiviral agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antiviral agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3443326